BIOAGE LABS, INC. Net Income
BIOAGE LABS, INC. (BIOA) reported Net Income of -$26.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-05
- BIOAGE LABS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$26.10M.
- BIOAGE LABS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$22.25M.
- BIOAGE LABS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$25.94M.
- BIOAGE LABS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$20.17M.
- BIOAGE LABS, INC. net income (loss) attributable to parent for fiscal 2025 was -$80.61M.
- BIOAGE LABS, INC. net income (loss) attributable to parent for fiscal 2024 was -$71.11M.
- BIOAGE LABS, INC. net income (loss) attributable to parent for fiscal 2023 was -$63.85M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$26.10M 10-Q · filed 2026-08-05 | -$48.35M 10-Q · filed 2026-08-05 | -$74.29M derived: sum of 3 quarters · filed 2026-08-05 | -$94.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$22.25M 10-Q · filed 2026-08-05 | -$48.20M derived: sum of 2 quarters · filed 2026-08-05 | -$68.37M derived: sum of 3 quarters · filed 2026-08-05 | -$89.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$25.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$46.11M derived: sum of 2 quarters · filed 2026-03-24 | -$67.68M derived: sum of 3 quarters · filed 2026-08-05 | -$80.61M 10-K · filed 2026-03-24 |
| 2025-09-30 | -$20.17M 10-Q · filed 2025-11-06 | -$41.73M derived: sum of 2 quarters · filed 2026-08-05 | -$54.66M 10-Q · filed 2025-11-06 | -$75.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$21.56M 10-Q · filed 2026-08-05 | -$34.49M 10-Q · filed 2026-08-05 | -$55.62M derived: sum of 3 quarters · filed 2026-08-05 | -$79.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$12.93M 10-Q · filed 2026-08-05 | -$34.06M derived: sum of 2 quarters · filed 2026-08-05 | -$57.46M derived: sum of 3 quarters · filed 2026-08-05 | -$71.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2024-12-31 | -$21.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$44.54M derived: sum of 2 quarters · filed 2026-03-24 | -$58.12M derived: sum of 3 quarters · filed 2026-03-24 | -$71.11M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$23.41M 10-Q · filed 2025-11-06 | -$36.99M derived: sum of 2 quarters · filed 2025-11-06 | -$49.98M 10-Q · filed 2025-11-06 | -$70.94M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$13.58M 10-Q · filed 2025-11-06 | -$26.57M 10-Q · filed 2025-08-06 | -$47.53M derived: sum of 3 quarters · filed 2025-11-06 | -$62.16M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | -$12.99M 10-Q · filed 2025-11-06 | -$33.95M derived: sum of 2 quarters · filed 2025-11-06 | -$48.58M derived: sum of 3 quarters · filed 2025-11-06 | -$65.76M derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | -$20.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$35.58M derived: sum of 2 quarters · filed 2025-03-20 | -$52.77M derived: sum of 3 quarters · filed 2025-03-20 | -$63.85M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$14.63M 10-Q · filed 2024-11-07 | -$31.81M derived: sum of 2 quarters · filed 2024-11-07 | -$42.90M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$17.19M 10-Q · filed 2024-11-07 | -$28.27M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | -$11.08M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |